UY33230A - Aminotiazolonas como moduladores del receptor alfa relacionados con estrógeno - Google Patents

Aminotiazolonas como moduladores del receptor alfa relacionados con estrógeno

Info

Publication number
UY33230A
UY33230A UY0001033230A UY33230A UY33230A UY 33230 A UY33230 A UY 33230A UY 0001033230 A UY0001033230 A UY 0001033230A UY 33230 A UY33230 A UY 33230A UY 33230 A UY33230 A UY 33230A
Authority
UY
Uruguay
Prior art keywords
modulators
alpha
estrogen
aminotiazolonas
alfa
Prior art date
Application number
UY0001033230A
Other languages
English (en)
Inventor
Bignan Gilles
Gaul Michael
Xu Guozhang
Bao-Ping Zhao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY33230A publication Critical patent/UY33230A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con nuevos compuestos de la Fórmula (I), métodos para preparar compuestos, composiciones, intermedios y derivados de estos y para el tratamiento de condiciones tales como, el cáncer, la artritis, la enfermedad inflamatoria de las vías respiratorias y trastornos metabólicos. Más particularmente, los compuestos de la presente invención son moduladores de los receptores de estrógeno alfa (ERR-a(alfa)) útiles para el tratamiento, mejorar o inhibir la progresión de estados de enfermedad, trastornos y condiciones mediadas por la actividad de ERR-a (alfa).
UY0001033230A 2010-02-17 2011-02-17 Aminotiazolonas como moduladores del receptor alfa relacionados con estrógeno UY33230A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30517710P 2010-02-17 2010-02-17

Publications (1)

Publication Number Publication Date
UY33230A true UY33230A (es) 2011-08-31

Family

ID=43920677

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033230A UY33230A (es) 2010-02-17 2011-02-17 Aminotiazolonas como moduladores del receptor alfa relacionados con estrógeno

Country Status (14)

Country Link
US (1) US8426604B2 (es)
EP (1) EP2536716B1 (es)
JP (1) JP2013519729A (es)
KR (1) KR20120133383A (es)
CN (1) CN102869660A (es)
AR (1) AR080206A1 (es)
AU (1) AU2011218268A1 (es)
BR (1) BR112012020604A2 (es)
CA (1) CA2789753A1 (es)
MX (1) MX2012009528A (es)
RU (1) RU2012139459A (es)
TW (1) TW201130831A (es)
UY (1) UY33230A (es)
WO (1) WO2011103130A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013051632A1 (ja) * 2011-10-04 2013-04-11 武田薬品工業株式会社 含窒素縮合複素環化合物
EP2832367B1 (en) 2012-03-26 2020-07-15 Nippon Chemiphar Co., Ltd. Agent for preventing or treating giant cell tumor or chondrosarcoma arising in bone/soft tissue
KR20220000993A (ko) 2013-09-25 2022-01-04 닛뽕 케미파 가부시키가이샤 골·연부에 발생하는 거세포성 종양, 연골육종 또는 골육종의 예방, 치료 또는 전이 예방을 위한 약제, 동맥색전술용 국소 주입제 및 인공골
TW201811752A (zh) * 2016-09-06 2018-04-01 比利時商健生藥品公司 用作升糖素受體拮抗劑之吲唑衍生物
CN112538038B (zh) * 2019-09-20 2022-05-20 暨南大学 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ378497A3 (cs) * 1995-06-02 1998-04-15 Synthelabo Deriváty oxazolidinonu, způsob jejich přípravy a jejich terapeutické použití
CN1246868A (zh) 1996-12-17 2000-03-08 扇形支撑剑桥有限公司 黑皮素
EA200700262A1 (ru) 2004-07-14 2007-08-31 Янссен Фармацевтика Н.В. Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа
US7977489B2 (en) * 2004-10-22 2011-07-12 Exelixis, Inc. Benzylthiazolone inhibitors of estrogen-related receptors (ERR)
UA98484C2 (ru) * 2007-03-07 2012-05-25 Янссен Фармацевтика Н.В. ЗАМЕЩЕННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ КАК МОДУЛЯТОРЫ α-РЕЦЕПТОРА ЭСТРОГЕНА

Also Published As

Publication number Publication date
JP2013519729A (ja) 2013-05-30
AR080206A1 (es) 2012-03-21
AU2011218268A1 (en) 2012-09-06
MX2012009528A (es) 2013-01-14
CA2789753A1 (en) 2011-08-25
CN102869660A (zh) 2013-01-09
RU2012139459A (ru) 2014-03-27
WO2011103130A1 (en) 2011-08-25
EP2536716B1 (en) 2014-05-21
US8426604B2 (en) 2013-04-23
WO2011103130A8 (en) 2012-09-13
KR20120133383A (ko) 2012-12-10
US20110200586A1 (en) 2011-08-18
TW201130831A (en) 2011-09-16
EP2536716A1 (en) 2012-12-26
BR112012020604A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
UY33231A (es) Aminotiazolonas como moduladores de los receptores de estrógenos alfa
CO2017013229A2 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares
PE20151141A1 (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CU20140055A7 (es) Procedimiento de preparación de 5- fluoro- 1h-pirazolopiridinas sustituidas
CO7141404A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CO7141403A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
ECSP11011517A (es) Compuestos antivirales
UY33735A (es) Compuestos antivirales
EA201692412A1 (ru) Синтез полициклических карбамоилпиридоновых соединений
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
GT201200201A (es) Moduladores alostéricos positivos de receptores m1 de la quinolina amida
CU20130040A7 (es) DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC
ECSP10010475A (es) Derivados de azetidina y ciclobutano como inhibidores de jak
CO6721019A2 (es) Quinazolincarboxamida azetidinas
UY33118A (es) Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos
CO6480975A2 (es) Mimetico de smac
BR112012021865A2 (pt) derivados de ceto benzofurano, assim com o respectivo processo de síntese e os intermediários.
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
CL2017000818A1 (es) Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii
CO6410257A2 (es) Herbicidas novedosos
CU24402B1 (es) 2,6 purinas di-sustituidas útiles en el tratamiento de trastornos proliferativos tales como cáncer
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
BR112014014939A2 (pt) composição de tratamento de sementes
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2